| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
||
| Other Sizes |
Purity: ≥98%
| Targets |
Ectonucleotide pyrophosphatase-phosphodiesterase 1 (ENPP-1).
|
|---|---|
| ln Vitro |
In vitro studies demonstrate that Enpp-1-IN-1 is a potent and selective inhibitor of ENPP-1 (nucleotide pyrophosphatase-phosphodiesterase 1). Inhibition of ENPP-1 by this compound enhances interferon-β (IFN-β) transcription induced by cGAMP in human foreskin fibroblasts HFF-1. This effect is mediated through the cGAS-STING pathway, where ENPP-1 normally degrades cGAMP, a second messenger that activates STING and induces type I interferon responses. By inhibiting ENPP-1, the compound increases cGAMP levels and potentiates STING-dependent IFN-β production. This mechanism positions Enpp-1-IN-1 as a valuable tool for studying the regulation of innate immune responses and nucleotide metabolism.
|
| ln Vivo |
In vivo studies on Enpp-1-IN-1 are limited, as the compound is primarily used as a research tool for in vitro investigations of ENPP-1 function and the cGAS-STING pathway. The compound's ability to enhance IFN-β transcription through ENPP-1 inhibition suggests potential applications in studying innate immune responses, antitumor immunity, and autoimmune diseases. Further studies are needed to assess the compound's pharmacokinetic properties, oral bioavailability, and efficacy in animal models of cancer and inflammatory diseases. The compound's selectivity for ENPP-1 makes it a valuable tool for validating this enzyme as a therapeutic target.
|
| Enzyme Assay |
ENPP-1 enzymatic activity assays are performed using purified recombinant ENPP-1 enzyme and a suitable substrate such as p-nitrophenyl thymidine 5'-monophosphate (pNP-TMP) or ATP. The enzyme is incubated with the substrate and varying concentrations of Enpp-1-IN-1, and the release of p-nitrophenol or inorganic phosphate is measured spectrophotometrically. IC50 values are calculated from dose-response curves to quantify the compound's potency against ENPP-1. Selectivity against related phosphodiesterases and nucleotide pyrophosphatases is assessed using similar biochemical assay formats to confirm the compound's specificity for ENPP-1.
|
| Cell Assay |
Cellular assays for Enpp-1-IN-1 typically involve culturing human foreskin fibroblasts (HFF-1) or other cell lines that express ENPP-1 and have functional cGAS-STING signaling. Cells are treated with cGAMP (a STING agonist) in the presence or absence of varying concentrations of Enpp-1-IN-1. IFN-β transcription is measured by quantitative RT-PCR or by using a luciferase reporter assay driven by the IFN-β promoter. The compound's ability to enhance cGAMP-induced IFN-β production is quantified, and EC50 values are calculated. ENPP-1 activity in cell lysates is measured to confirm target engagement. Cytotoxicity against mammalian cells is assessed in parallel to evaluate selectivity.
|
| Animal Protocol |
In vivo efficacy of Enpp-1-IN-1 is evaluated in mouse models of cancer or inflammatory diseases where the cGAS-STING pathway plays a role. Tumor-bearing mice are treated with the compound via oral or intraperitoneal administration, and tumor growth and immune cell infiltration are monitored. Alternatively, in models of autoimmune or inflammatory diseases, the compound's ability to modulate IFN-β production and immune responses is assessed. Endpoints include measurement of cytokine levels in serum and tissues, immune cell phenotyping by flow cytometry, and histopathological examination of affected tissues. Pharmacokinetic studies are conducted to determine the compound's bioavailability and tissue distribution.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Enpp-1-IN-1 have been characterized in preclinical studies to support its use as a research tool. The compound's molecular weight of 343.4 and chemical properties influence its absorption, distribution, metabolism, and excretion (ADME) characteristics. Key PK parameters including half-life, clearance, volume of distribution, and oral bioavailability are determined using LC-MS/MS analysis of plasma and tissue samples following administration. The compound's pharmacokinetic profile is important for designing in vivo studies and for interpreting the relationship between drug exposure and biological effects in animal models.
|
| Toxicity/Toxicokinetics |
Toxicological evaluation of Enpp-1-IN-1 is typically conducted in parallel with efficacy studies in cell-based and animal models. Standard toxicology assessments include in vitro cytotoxicity assays against a panel of normal and cancer cell lines to determine the compound's selectivity index. In vivo toxicity studies in rodents include acute toxicity testing to determine the maximum tolerated dose, observation of clinical signs and body weight changes, and histopathological examination of major organs following repeated dosing. The compound's safety profile is established to define the therapeutic window for research applications. As an ENPP-1 inhibitor, potential effects on nucleotide metabolism and immune function are carefully monitored.
|
| References | |
| Additional Infomation |
Enpp-1-IN-1 is a research tool compound used for studying ENPP-1 biology and its role in the cGAS-STING pathway, nucleotide metabolism, and immune regulation. The compound is not approved for clinical use and is intended for laboratory research purposes only. Its mechanism of action involves inhibition of ENPP-1 enzymatic activity, which prevents the degradation of cGAMP, a STING agonist, leading to enhanced IFN-β transcription and potentiation of innate immune responses. This compound is valuable for validating ENPP-1 as a therapeutic target for cancer immunotherapy, antiviral therapy, and the treatment of inflammatory diseases.
|
| Molecular Formula |
C17H17N3O3S
|
|---|---|
| Molecular Weight |
343.40018248558
|
| Exact Mass |
343.099
|
| Elemental Analysis |
C, 59.46 H, 4.99 N, 12.24 O, 13.98 S, 9.34
|
| CAS # |
2289728-58-9
|
| PubChem CID |
137524159
|
| Appearance |
White to off-white solid powder
|
| LogP |
2
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
24
|
| Complexity |
500
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
S(N)(NCC1C=CC(=CC=1)C1C=CN=C2C=C(C=CC=12)OC)(=O)=O
|
| InChi Key |
UEJMNZDIQDULLP-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C17H17N3O3S/c1-23-14-6-7-16-15(8-9-19-17(16)10-14)13-4-2-12(3-5-13)11-20-24(18,21)22/h2-10,20H,11H2,1H3,(H2,18,21,22)
|
| Chemical Name |
N-[4-(7-Methoxyquinolin-4-yl)benzyl]sulfamide
|
| Synonyms |
Enpp-1-IN 1 Enpp-1-IN1 MV 658 MV-658 MV658
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~728.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (6.06 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (6.06 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (6.06 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.9121 mL | 14.5603 mL | 29.1206 mL | |
| 5 mM | 0.5824 mL | 2.9121 mL | 5.8241 mL | |
| 10 mM | 0.2912 mL | 1.4560 mL | 2.9121 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA